© The Royal Society of Chemistry 2021. In this chapter, we discuss the rise and rationale for public-private partnerships (PPP) in phenotypic drug discovery (PDD) from both the academic and industrial perspectives. We then give a review of the three most common "precompetitive"PPP in PDD formats, namely collaborative, co-localized and industry-supported, before finally providing an outlook/conclusion, highlighting the factors we feel contribute to successful PDD partnerships, and the directions we feel these partnerships could take to improve outcomes for both partners.
RSC Drug Discovery Series
118 - 139